Stock Market Reviews

VNDA (Vanda Pharmaceuticals Inc.) News

Get the latest news, insights, and market updates on VNDA (Vanda Pharmaceuticals Inc.). Explore the news page 3 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Sector Update: Health Care Stocks Lean Lower Premarket Wednesday
  Health care stocks were leaning lower premarket Wednesday, with the State Street Health Care Select
  Dec 31, 2025 - $VNDA
• Biggest Mover Wednesday: Vanda's FDA Win Sends the Stock Flying
  The FDA Finally Has a New Answer for Motion Sickness. Vanda Stock Is Surging.
  Dec 31, 2025 - $VNDA
• Vanda Pharmaceuticals Shares Jump 30% on Motion Sickness Drug Approval
  The FDA approved Vanda’s drug Nereus to prevent motion-induced vomiting, opening a potential path into treating nausea linked to GLP-1 weight-loss drugs.
  Dec 31, 2025 - $VNDA
• Vanda Pharmaceuticals Announces FDA Approval of NEREUS™ (tradipitant) for the Prevention of Vomiting Induced by Motion: A Historic Scientific Milestone in the Prevention of Motion Sickness
  Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has approved NEREUS™ (tradipitant), an oral neurokinin-1 (NK-1) receptor antagonist, for the prevention of vomiting induced by motion. This approval marks the first new pharmacologic treatment in motion sickness in over four decades, representing a significant advancement in the understanding and management of this debilitating physiologic response that affects a substantial portion
  Dec 30, 2025 - $VNDA
• 3 Biotech Stocks With Major 2026 Catalysts
  Biotech's 2025 rebound sets the stage for Denali Therapeutics and two peers, with key FDA decisions and pipeline catalysts lined up for 2026.
  Dec 29, 2025 - $VNDA
• Vanda Announces Submission of Biologics License Application to the FDA for Imsidolimab for the Treatment of Generalized Pustular Psoriasis
  Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for imsidolimab, a novel IgG4 IL-36 receptor antagonist, to treat generalized pustular psoriasis (GPP). Imsidolimab inhibits IL-36 receptor signaling, addressing the deficiency in the endogenous IL-36RA regulator commonly seen in GPP patients due to IL36RN gene mutations.
  Dec 15, 2025 - $VNDA
• Vanda Pharmaceuticals Announces Participation in the J.P. Morgan Healthcare Conference
  Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in the J.P. Morgan Healthcare Conference in San Francisco, California on Thursday, January 15, 2026. A corporate presentation is scheduled for 9:00 a.m. Pacific Time (12:00 p.m. Eastern Time).
  Dec 11, 2025 - $VNDA
• FDA Lifts Partial Clinical Hold on Tradipitant for Motion Sickness
  Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has lifted the partial clinical hold on protocol VP-VLY-686-3403, which until today limited the protocol to a maximum of 90 doses of tradipitant.
  Dec 4, 2025 - $VNDA
• Vanda Pharmaceuticals Provides Regulatory Update on Tradipitant for Motion Sickness
  Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA), today announced the following updates regarding tradipitant for motion sickness:
  Nov 28, 2025 - $VNDA
• Vanda Pharmaceuticals Leads 3 Promising Penny Stocks
  As the U.S. markets navigate a volatile landscape marked by significant swings in major stock indexes, investors are increasingly seeking opportunities beyond the usual tech giants. Penny stocks, often representing smaller or newer companies, continue to pique interest despite their somewhat outdated label. These stocks can offer surprising value and potential growth when backed by strong financial health, making them an intriguing option for those looking to explore diverse investment avenues.
  Nov 21, 2025 - $VNDA